{'fraction_non_alphanumeric': 0.022413793103448276, 'fraction_numerical': 0.0017241379310344827, 'mean_word_length': 5.829411764705882, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A novel non‐toxic histone deacetylase inhibitor enhances spatial memory consolidation in male mice

Memory dysfunction is a hallmark of Alzheimer’s disease (AD) and other dementias, yet truly effective treatments for memory loss do not exist. Memory dysfunction stems in part from reduced gene expression that leads to decreased levels of proteins essential for neural plasticity. Gene expression is facilitated by histone acetylation, an epigenetic mechanism that regulates chromatin accessibility. Compounds that maintain histone acetylation, called histone deacetylase inhibitors (HDACi), enhance memory by preventing deacetylation of core histone proteins, which allows for transcriptional machinery to bind open chromatin and increase gene expression. Although HDACi are promising therapeutics that could be used to prevent or delay memory loss associated with AD and other dementias, existing HDACi have poor solubility and undesirable toxicity. To address these shortcomings, our group has developed a novel HDACi compound, MJM‐1, that is brain‐penetrant and shows no evidence of toxicity. Here, we determine the extent to which MJM‐1can enhance memory.